SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

R1 Therapeutics Presents Phase IIb Trial Design for AP306

Alebund Pharmaceuticals said its partner R1 Therapeutics presented a poster outlining the design of a global, multi-regional Phase IIb clinical trial for AP306 at ASN Kidney Week 2026.

Related stories